ReviewThe Journal of antimicrobial chemotherapy2009
Eradication of HIV: current challenges and new directions.
Review in The Journal of antimicrobial chemotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 66 citations in OpenAlex.
- Review
- Review
- Impact of fluctuation in frequency of human immunodeficiency virus/simian immunodeficiency virus reactivation during antiretroviral therapy interruption.Proceedings. Biological sciences · 2020Article
- Phyloanatomic characterization of the distinct T cell and monocyte contributions to the peripheral blood HIV population within the host.Virus evolution · 2020Article
- Reverse Transcriptase Inhibitors Nanosystems Designed for Drug Stability and Controlled Delivery.Pharmaceutics · 2019Review
- Modulating cellular autophagy for controlled antiretroviral drug release.Nanomedicine (London, England) · 2018Article
- Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.Virology · 2018Article
- M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures.Scientific reports · 2017Article
- Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS.Advanced drug delivery reviews · 2016Review
- Progress and challenges in the use of latent HIV-1 reactivating agents.Acta pharmacologica Sinica · 2015Review
- Apoptosis-induced activation of HIV-1 in latently infected cell lines.Retrovirology · 2015Article
- Article
- Designed transcription activator-like effector proteins efficiently induced the expression of latent HIV-1 in latently infected cells.AIDS research and human retroviruses · 2015Article
- Recent developments in human immunodeficiency virus-1 latency research.The Journal of general virology · 2013Review
- Targeting IκB proteins for HIV latency activation: the role of individual IκB and NF-κB proteins.Journal of virology · 2013Article
- Article
- Successful isolation of infectious and high titer human monocyte-derived HIV-1 from two subjects with discontinued therapy.PloS one · 2013Article
- HIV-1 induces telomerase activity in monocyte-derived macrophages, possibly safeguarding one of its reservoirs.Journal of virology · 2012Article
- Hematopoietic precursor cells isolated from patients on long-term suppressive HIV therapy did not contain HIV-1 DNA.The Journal of infectious diseases · 2012Article
- Nanotechnology and the treatment of HIV infection.Viruses · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Highly active antiretroviral therapy (HAART) can potently suppress human immunodeficiency virus (HIV) replication and prevent progression to AIDS. However, HAART does not cure infected patients. Instead, HIV persists in latently infected CD4+ T cells and various cryptic cellular reservoirs. Hence, under current therapy regimens, patients must continue taking HAART for the remainder of their lives. Eliminating residual replication-competent virus is critical if eradication of HIV is to be achieved. While this challenge is formidable, we describe here a number of innovative approaches intended to further deplete HIV in HAART-treated patients. New antiretroviral drugs that target different viral proteins and stages of the virus life cycle, compounds that enhance anti-HIV immune responses and novel gene therapy approaches may each play a role in improving long-term suppression of the virus. Moreover, methods for more specifically and efficiently inducing HIV from latency and eliminating the newly activated host cells are also under development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.